Business Context and Reporting Period
This Form 8-K Current Report was filed by MapLight Therapeutics, Inc. on April 29, 2026, covering events occurring on April 23, 2026. The Company is a Delaware corporation with its principal executive offices in Redwood City, California, and its common stock trades on the Nasdaq Global Select Market under the symbol MPLT.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On April 23, 2026, two directors notified the Board of their decision not to stand for reelection at the Annual Meeting of Stockholders scheduled for June 23, 2026:
- Robert Malenka, M.D., Ph.D.
- Jim Trenkle, Ph.D.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace the departing directors. The Company explicitly stated that these departures were not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the director departures and the subsequent nomination of replacements.
Key Facts for Investor Verification
- Confirm the election results for Martin Babler and Troy Cox at the June 23, 2026, Annual Meeting.
- Verify the professional backgrounds and qualifications of the new director nominees.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.